{"text": "TITLE:\n      OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study\nSUMMARY:\n      The purpose of this study is to investigate whether high-dose angiotensin II receptor\n      blocker (ARB) monotherapy or combination therapy with ARB and calcium channel blockers is\n      more effective in reducing the incidence of cardiovascular events in Japanese elderly\n      high-risk hypertensive patients not adequately controlled by standard dose ARB alone.\nDETAILED DESCRIPTION:\n      Hypertension is one of the major risk factors of cardiovascular diseases. It is also\n      important for elderly hypertensive patients to strictly reduce their blood pressures to\n      prevent cardiovascular events. Although angiotensin II receptor blockers (ARBs) are\n      increasingly used in antihypertensive treatment recently, few studies have been performed in\n      Japan to assess the difference between high-dose ARB monotherapy and combination therapy of\n      ARB with calcium channel blocker (CCB) in prevention of cardiovascular diseases for patients\n      whose blood pressure is not well controlled by ARB monotherapy. OSCAR-study is a\n      multicenter, active-controlled, 2-arm parallel group comparison, prospective randomized open\n      blinded end-point (PROBE) design study. The dose administered is olmesartan medoxomil\n      20mg/day as ARB monotherapy in the 'Step 1' period. If the blood pressure is not adequately\n      controlled and treatment is well tolerated then the dose is changed to olmesartan medoxomil\n      40mg/day in the high-dose ARB monotherapy group, or olmesartan medoxomil 20mg/day and a CCB\n      in the combination therapy group in the 'Step 2' period. At least 500 patients will be\n      enrolled in each group, and the follow-up duration will be 3 years. The primary objective is\n      to compare the incidence of a composite of fatal and non-fatal cardiovascular events, and\n      all cause mortality between the two treatment groups.\nELIGIBILITY CRITERIA:\n      Inclusion Criteria:\n          -  Outpatients aged 65 years or older, and less than 85 years (at the time of informed\n             consent), regardless of sex\n          -  Current antihypertensive treatment with monotherapy\n          -  SBP \u2265 140mmHg or DBP \u2265 90mmHg in a sitting position on two measurements on two clinic\n             visits\n          -  At least one of the following risk factors:\n               -  Diabetes mellitus Type 2;\n               -  History of cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, or\n                  transient ischemic attack (more than 6 months before giving informed consent);\n               -  Diagnosis of asymptomatic cerebrovascular disease;\n               -  History of myocardial infarction (more than 6 months before giving informed\n                  consent);\n               -  Diagnosis of angina pectoris or heart failure (New York Heart Association [NYHA]\n                  functional classification I or II);\n               -  Diagnosis of left ventricular hypertrophy (thickness of the wall of\n                  interventricular septum \u2265 12mm on echocardiography or Sv1+Rv5 \u2265 35mm on\n                  electrocardiography before informed consent);\n               -  Diagnosis of aortic aneurysm;\n               -  History of aortic dissection (more than 6 months before giving informed\n                  consent);\n               -  Diagnosis of arteriosclerotic peripheral arterial obstruction (Fontaine\n                  classification from 2 to 4);\n               -  Serum creatinine: 1.2-2.5mg/dL (male); 1.0-2.5mg/dL (female);\n               -  Proteinuria: \u2265 +1 (or \u2265 0.3g/g\uff65Cr. estimated from 24-hour urine collection or\n                  random urinary protein corrected by urine creatinine).\n        Exclusion Criteria:\n          -  Secondary hypertension or malignant hypertension\n          -  Heart failure (NYHA functional classification III or IV)\n          -  Required treatment for malignant tumor\n          -  Serious liver or renal dysfunction (serum creatinine > 2.5mg/dL or with dialysis\n             treatment)\n          -  Not appropriate for change to the test drugs from current therapy for hypertension or\n             coronary diseases (i.e. calcium channel blockers, \u03b2-blockers, thiazide diuretics,\n             etc.)\n          -  History of serious adverse drug reactions to angiotensin II receptor blockers or\n             calcium channel blockers\n          -  Patients with other serious reasons (i.e. illness, significant abnormalities, etc.)\n             that investigators judge inappropriate for the study\n", "cuis": "C0006675 C0201925 C2936886 C3540037 C1654653 C0947630 C1511238 C3897779 C1552616 C1706244 C0003009 C0373546 C0523498 C0003018 C0051863 C0051887 C0051889 C0603886 C0947630 C0700651 C0006684 C0872271 C0005116 C0009429 C0556895 C1320716 C0857121 C0947663 C0003364 C0038137 C2828392 C3272550 C0180112 C2911690 C0678257 C0033080 C1521941 C0007222 C0455539 C0348668 C1290379 C0455404 C0042373 C0558373 C0020538 C1963138 C3248638 C0947663 C0085580 C0455405 C1696708 C3829824 C0455624 C1553898 C4036105 C0455939 C0005823 C0005824 C1272641 C0020649 C0725357 C2230142 C0020538 C2926615 C0180208 C0428889 C0428886 C0488053 C0497247 C0204939 C0436781 C0476712 C0580944 C0849842 C4071679 C0857121 C0947663 C0003364 C1320716 C0003009 C0373546 C0523498 C0003018 C0051863 C0051887 C0051889 C0603886 C1979715 C0003364 C0857121 C0087111 C3887704 C0376495 C1533734 C0746919 C0814472 C3647788 C0947630 C0009429 C0556895 C0085632 C3842396 C0006684 C0872271 C0358701 C0573229 C0007222 C0455539 C0348668 C1290379 C0455404 C0042373 C0558373 C0199176 C0175556 C0005823 C0005824 C1272641 C0020649 C0725357 C2230142 C0020538 C2926615 C0180208 C0428889 C0428886 C0488053 C0497247 C0947630 C0180112 C2911690 C1320102 C0180112 C2911690 C1552839 C0386393 C1177273 C0182400 C0728863 C0947630 C1536013 C1536235 C0005823 C0005824 C1272641 C0020649 C0725357 C2230142 C0020538 C2926615 C0180208 C0428889 C0428886 C0488053 C0497247 C0025344 C1561538 C0386393 C1177273 C0087111 C3887704 C0376495 C1533734 C0746919 C0814472 C3647788 C0180112 C2911690 C0442739 C0386393 C1177273 C1561538 C0175556 C1552839 C0009429 C0556895 C0025344 C1552839 C0018017 C2239270 C2979883 C0332534 C0720099 C2926735 C1552839 C1320716 C0087111 C3887704 C0376495 C1533734 C0746919 C0814472 C3647788 C1552839 C0243161 C0013893 C0243161 C3843802 C0562357 C0009253 C0003364 C0857121 C0087111 C3887704 C0376495 C1533734 C0746919 C0814472 C3647788 C0277814 C3166408 C1301304 C1306620 C1305849 C0423103 C2048307 C3838520 C1512346 C0455624 C1553898 C4036105 C0455939 C0011849 C1313937 C1552651 C0038525 C0475872 C0348633 C3665730 C0854172 C3839590 C0007785 C0393952 C1536121 C0348636 C2937358 C0007784 C0565621 C0472374 C0262926 C2004062 C0007787 C0917805 C0009797 C1561542 C0007820 C0585890 C0393949 C0810006 C0553766 C0393950 C0231221 C0343751 C0011900 C0945731 C1275835 C0455406 C0155668 C1579478 C0562357 C1561542 C0002962 C0455530 C0018801 C0018802 C0004083 C0086168 C0011900 C0945731 C0018787 C0153500 C0153957 C1281570 C0444594 C0457356 C0596463 C1275491 C0031843 C0149721 C0232306 C3484363 C2103992 C0340279 C0745681 C0344398 C0162770 C0281788 C3476091 C0011900 C0945731 C0225870 C0225881 C1442293 C0504011 C1284316 C2325343 C1401138 C2335478 C0013516 C0183129 C0203378 C0013524 C0203379 C0221533 C0412564 C0013798 C1623258 C0180600 C0009797 C0003486 C2072946 C0459854 C0554762 C0011900 C0945731 C0340643 C0241868 C0262926 C2004062 C0562357 C1561542 C0264995 C0011900 C0945731 C0444594 C0457356 C0596463 C1275491 C0201976 C0600061 C0858112 C0428282 C0033687 C1962972 C0042036 C0591833 C0034770 C0600644 C0428283 C1318439 C0428287 C0236441 C0033621 C1949480 C0038164 C0243161 C0155616 C0155620 C0348586 C0020540 C0024588 C0018801 C0018802 C0444594 C0457356 C0596463 C1275491 C0031843 C0006826 C0086692 C0496836 C0087111 C3887704 C0376495 C1533734 C0746919 C0814472 C3647788 C1619636 C3245501 C3245502 C0201976 C0600061 C0858112 C0428282 C0011946 C1654851 C1551395 C1552745 C0023884 C0022646 C0277785 C0087111 C3887704 C0376495 C1533734 C0746919 C0814472 C3647788 C0020538 C1963138 C1696708 C2748577 C0947663 C0087111 C0033972 C0013227 C0392366 C0456984 C0006684 C0872271 C0005116 C0012802 C0010068 C1956346 C0041755 C1963760 C1716142 C1161049 C3244242 C0003009 C0373546 C0523498 C0003018 C0051863 C0051887 C0051889 C0603886 C0262926 C2004062 C1979715 C0006684 C0872271 C0005116 C0221423 C0424228 C1550655 C1578485 C1578486 C2360836 C2360838 C2360840 C3809765 C0015393 C0151583 C0151611 C0476403 C0522214 C1832603 C2183966 C2674738 C0947630 C0021141 ", "concepts": "Calcium, Calcium, Calcium, Calcium, O-Calcium, Study, BN Antagonists, Randomiz summary, summary angiotensin ii, Angiotensin II, Angiotensin I, angiotensin, SMT-angiotensin II, NAB angiotensin II, Br5-angiotensin II, SAMP-angiotensin II, study, Eureceptor calcium channel blocker, sodium channel blockers, calcium channel blockers bepridil, combination therapies, combination therapies cardiovascular events hypertensive, hypertensin, Antihypertensive, standards, Standard, Standard, controllers, Controlled description, prescription, prescription CVD - cardiovascular disease, H/O: cardiovascular disease, Other cardiovascular disease, Acute cardiovascular disease, FH: Cardiovascular disease, vascular diseases, Preg.+ cardiovascular disease, Hypertension NOS, Hypertension, Hypertension mg, Hypertensin, Hypertension NOS, FH: Hypertension, Pre-Hypertension, Has Hypertension, risk factors, risk factors, No risk factors, A/N risk factors Blood pressure, take blood pressure, blood pressures, Blood pressure low, blood pressure kit, blood pressure leg, high; blood pressure, High blood pressure, blood pressure cuffs, Cuff blood pressure, mean blood pressure, Mean blood pressure, blood pressure rises, Teach blood pressure, O/E - blood pressure, test; blood pressure, Lying blood pressure, blood pressure check, Aorta blood pressure, hypertensive, hypertensin, Antihypertensive cardiovascular events, angiotensin ii, Angiotensin II, Angiotensin I, angiotensin, SMT-angiotensin II, NAB angiotensin II, Br5-angiotensin II, SAMP-angiotensin II, H2 receptor blockers antihypertensive, hypertensive, Treatment, treatment, Retreatment, Treatment, no treatment, co-treatment, maltreatment, studies combination therapies, combination therapies, Indifference, No difference calcium channel blocker, sodium channel blocker, Atenolol+calcium channel blocker, calcium channel blocker overdose, CVD - cardiovascular disease, H/O: cardiovascular disease, Other cardiovascular disease, Acute cardiovascular disease, FH: Cardiovascular disease, vascular diseases, Preg.+ cardiovascular disease, prevention, ccb Blood pressure, take blood pressure, blood pressures, low blood pressures, blood pressure kit, blood pressure leg, high blood pressure, High blood pressure, blood pressure cuff, Cuff blood pressure, mean blood pressure, Mean blood pressure, blood pressure rise, study, controllers, Controlled Factive, controllers, Controlled, groups olmesartan medoxomil, Olmesartan medoxomil 5 MG, probes, probe, study, Wrong dose administered, Extra dose administered Blood pressure, take blood pressure, blood pressures, low blood pressures, blood pressure kit, blood pressure leg, high blood pressure, High blood pressure, blood pressure cuff, Cuff blood pressure, mean blood pressure, Mean blood pressure, blood pressure rise, period, day olmesartan medoxomil, Olmesartan medoxomil 5 MG, Treatment, treatment, Retreatment, Treatment, no treatment, co-treatment, maltreatment, controllers, Controlled, Unchanged olmesartan medoxomil, Olmesartan medoxomil 5 MG, day, ccb, groups combination therapies, combination therapies, period, groups Objective, objective, Objective, Induration, Duration, Duration, groups cardiovascular events Treatment, treatment, Retreatment, Treatment, no treatment, co-treatment, maltreatment, groups criteria, Eligibility Criteria 65 years old or older, Uninformed sex antihypertensive, hypertensive, Treatment, treatment, Retreatment, Treatment, no treatment, co-treatment, maltreatment sitting position, Testing position, Fitting point position, sbp, dbp, Eye measurements, ICD measurements, arm measurements visit risk factors, risk factors, No risk factors, A/N risk factors Diabetes mellitus, NOS, FH: Diabetes mellitus, Type SAH - Subarachnoid hemorrhage, H/O subarachnoid hemorrhage, [X]Other subarachnoid hemorrhage, Spinal subarachnoid hemorrhage, neonatal subarachnoid hemorrhage, Convexal subarachnoid hemorrhage, Cerebral infarction NOS, precerebral infarction, Old cerebral infarction, Other cerebral infarction, intracerebral hemorrhages, Cerebral hemorrhage, Fetal cerebral hemorrhage, Lobar cerebral hemorrhage, History, History Transient ischemic attack, Transient ischemic attacks, informed consent form, month CVD - Cerebrovascular disease, H/O: cerebrovascular disease, Other cerebrovascular diseases, Acute cerebrovascular disease, Diffuse cerebrovascular disease, Other cerebrovascular disease OS, asymptomatic, asymptomatic HIV, {Diagnosis}, Diagnosis History of myocardial infarction (situation), Family history of myocardial infarction, Personal history of myocardial infarction, [V]Family history of myocardial infarction, Uninformed, month angina pectoris, H/O: angina pectoris, heart failures, Heart failure, Association, Dissociation, {Diagnosis}, Diagnosis, Hearts, Heart, Heart, Heart Gass classification, Kiel classification, drug classification, nyha classification, function hypertrophy left ventricular, Left ventricular hypertrophy by EKG, Left ventricular hypertrophy, left ventricular hypertrophy eccentric, ventricular hypertrophy, left ventricular hypertrophy concentric, ECG: Left ventricular hypertrophy, Right ventricular hypertrophy, Biventricular hypertrophy, Left ventricular hypertrophy change, {Diagnosis}, Diagnosis interventricular septum, Muscular interventricular septum, Heart.interventricular septum, Bulbar interventricular septum, Entire interventricular septum, Anterior interventricular septum, interventricular septum; closure, Inferior interventricular septum, echocardiogram, echocardiographs, 3D Echocardiography, 2D Echocardiography, 4D Echocardiography, cardiography, Fetal echocardiography electrocardiogram, electrocardiogram, Electrocardiographs, informed consent form aortic aneurysms, aortic aneurysm, H/O: aortic aneurysm, Aortic aneurysm CT, {Diagnosis}, Diagnosis aortic dissection, acute aortic dissection, History, History, Uninformed, month arterial obstruction, {Diagnosis}, Diagnosis Gass classification, Kiel classification, drug classification, nyha classification Serum creatinine NOS, Serum creatinine level, Serum creatine, Serum creatinine low Proteinurias, Proteinuria, urine, Murine, Recollection, Collections urine creatinine level, urine creatinine, urine creatine, urine creatinine test, protein C, protein C, a protein Criteria Secondary hypertension, Secondary hypertension, benign, Other secondary hypertension, Malignant hypertension NOS, Malignant hypertension Heart failures, Heart failure, Gass classification, Kiel classification, drug classification, nyha classification, function malignant tumor, nonmalignant tumor, eye malignant tumors, Treatment, treatment, Retreatment, Treatment, no treatment, co-treatment, maltreatment, Required, required, required serum creatinine test, serum creatinine level, serum creatine, low serum creatinine, Dialysis, Dialysis, Serious, Serious, liver, renal, Dysfunction Treatment, treatment, Retreatment, Treatment, no treatment, co-treatment, maltreatment hypertension, Hypertension, Prehypertensions, No hypertension, hypertensin, therapy, Cotherapy, drugs, test, test calcium channel blocker, sodium channel blockers, calcium channel blockers bepridil, thiazide diuretics, coronary disease, Coronary disease Adverse drug reaction NOS, No adverse drug reaction, Adverse drug reaction Hx, Assess adverse drug reactions, adverse drug reaction access, angiotensin ii, Angiotensin II, Angiotensin I, angiotensin, SMT-angiotensin II, NAB angiotensin II, Br5-angiotensin II, SAMP-angiotensin II, History, History, H2 receptor blockers calcium channel blocker, sodium channel blockers, calcium channel blockers bepridil illness, Stillness, Patient, Patient, Patient, Patient, Patient, Patient, No abnormalities, abnormalities eye, abnormalities csf, EEG abnormalities, EMG abnormalities, VEP abnormalities, Ekg abnormalities, lip abnormalities, Toe abnormalities study, ADH inappropriate "}
